AIDS Scholarly Peer-review Journal
No cure is currently available for HIV or AIDS.
Be that as it may, medicines can stop the movement of the condition and permit a great many people living with HIV the chance to live a long and generally sound life.
Beginning ART right off the bat in the movement of the infection is essential. This improves personal satisfaction, broadens future, and diminishes the danger of transmission, as per the WHO's rules from June 2013.
Increasingly compelling and better-endured medicines have developed that can improve general wellbeing and personal satisfaction by taking as meager as one pill for each day.
An individual living with HIV can diminish their viral burden to such an extent, that it is not, at this point distinguishable in a blood test. In the wake of evaluating various enormous investigations, the CDC reasoned that people who have no perceivable viral burden "have successfully no danger of explicitly transmitting the
infection to a HIV-contrary accomplice.
The treatment of HIV includes antiretroviral meds that battle the HIV contamination and hinders the spread of the
infection in the body. Individuals living with HIV for the most part take a mix of meds called exceptionally dynamic
antiretroviral treatment (HAART) or blend antiretroviral treatment (cART).
High Impact List of Articles
-
Recent trial results in recombinant coagulation factors for the treatment of hemophilia B
Julie Jaffray & Guy Young
Clinical Trail Outcomes: Clinical Investigation
-
Recent trial results in recombinant coagulation factors for the treatment of hemophilia B
Julie Jaffray & Guy Young
Clinical Trail Outcomes: Clinical Investigation
-
Recent trial results in recombinant coagulation factors for the treatment of hemophilia B
Julie Jaffray & Guy Young
Clinical Trail Outcomes: Clinical Investigation
-
Recent trial results in recombinant coagulation factors for the treatment of hemophilia B
Julie Jaffray & Guy Young
Clinical Trail Outcomes: Clinical Investigation
-
Recent trial results in recombinant coagulation factors for the treatment of hemophilia B
Julie Jaffray & Guy Young
Clinical Trail Outcomes: Clinical Investigation
-
Recent trial results in recombinant coagulation factors for the treatment of hemophilia B
Julie Jaffray & Guy Young
Clinical Trail Outcomes: Clinical Investigation
-
Changing the paradigm: circulating tumor DNA as a liquid biopsy for clinical biomarker assessments
Timothy R Wilson & Mark R Lackner
Clinical Trail Methodology: Clinical Investigation
-
Changing the paradigm: circulating tumor DNA as a liquid biopsy for clinical biomarker assessments
Timothy R Wilson & Mark R Lackner
Clinical Trail Methodology: Clinical Investigation
-
Changing the paradigm: circulating tumor DNA as a liquid biopsy for clinical biomarker assessments
Timothy R Wilson & Mark R Lackner
Clinical Trail Methodology: Clinical Investigation
-
Changing the paradigm: circulating tumor DNA as a liquid biopsy for clinical biomarker assessments
Timothy R Wilson & Mark R Lackner
Clinical Trail Methodology: Clinical Investigation
-
Changing the paradigm: circulating tumor DNA as a liquid biopsy for clinical biomarker assessments
Timothy R Wilson & Mark R Lackner
Clinical Trail Methodology: Clinical Investigation
-
Changing the paradigm: circulating tumor DNA as a liquid biopsy for clinical biomarker assessments
Timothy R Wilson & Mark R Lackner
Clinical Trail Methodology: Clinical Investigation
-
Ulipristal acetate (ellaOne) for emergency contraception: review of the clinical evidence
Kristina Gemzell-Danielsson,Sharon T Cameron
Review Article: Clinical Investigation
-
Ulipristal acetate (ellaOne) for emergency contraception: review of the clinical evidence
Kristina Gemzell-Danielsson,Sharon T Cameron
Review Article: Clinical Investigation
-
Ulipristal acetate (ellaOne) for emergency contraception: review of the clinical evidence
Kristina Gemzell-Danielsson,Sharon T Cameron
Review Article: Clinical Investigation
-
Ulipristal acetate (ellaOne) for emergency contraception: review of the clinical evidence
Kristina Gemzell-Danielsson,Sharon T Cameron
Review Article: Clinical Investigation
-
Ulipristal acetate (ellaOne) for emergency contraception: review of the clinical evidence
Kristina Gemzell-Danielsson,Sharon T Cameron
Review Article: Clinical Investigation
-
Ulipristal acetate (ellaOne) for emergency contraception: review of the clinical evidence
Kristina Gemzell-Danielsson,Sharon T Cameron
Review Article: Clinical Investigation
-
Targeting ischemic penumbra Part I: from pathophysiology to therapeutic strategy
Shimin Liu, Steven R. Levine and H. Richard Winn
Review Article: Journal of Experimental Stroke & Translational Medicine
-
Targeting ischemic penumbra Part I: from pathophysiology to therapeutic strategy
Shimin Liu, Steven R. Levine and H. Richard Winn
Review Article: Journal of Experimental Stroke & Translational Medicine
-
Golimumab: a new anti-TNF agent on the horizon for inflammatory arthritis
S Bhagat, B Dasgupta & MU Rahman
Discussion Paper: International Journal of Clinical Rheumatology
-
Golimumab: a new anti-TNF agent on the horizon for inflammatory arthritis
S Bhagat, B Dasgupta & MU Rahman
Discussion Paper: International Journal of Clinical Rheumatology
Relevant Topics in Clinical